Investor Relations

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, Maveropepimut-S (DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing Maveropepimut-S as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.

View Management Team View Board of Directors

Investor Relations

Upcoming Event

BTIG Virtual Biotechnology Conference Fireside Chat

Latest News

IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021

Latest Presentation

Corporate Presentation

Latest Financial Results

Q1 2021

Latest Annual Filing

Stock Snapshot

Company Overview

Investor Contact Information

Headquarters

Corporate Office